Literature DB >> 7370291

Quantitative determination of human apolipoprotein C-III by electroimmunoassay.

M D Curry, W J McConathy, J D Fesmire, P Alaupovic.   

Abstract

An electroimmunoassay procedure is described for the quantitative determination of human plasma apolipoprotein C-III. Purified apolipoprotein C-III was used for the preparation of monospecific antisera and as the primary standard. This sensitive, specific, rapid (time required for the completion of the assay is 5 h), precise (the within and between-assay coefficients of variation are 6 and 8%, respectively) and accurate electroimmunoassay is applicable to measurement of C-III polypeptide in whole serum and density classes. However, plasma samples containing lipoproteins with Sf less than 400 and/or triacylglycerol levels greater than 700 mg/100 ml must be delipidized. Plasma apolipoprotein C-III levels of normolipidemic subjects and hypercholesterolemic (type IIa) patients were similar (10.4 +/- 3 and 12.0 +/- 6 mg/100 ml, respectively). In contrast, patients with hyperlipoproteinemic phenotypes IIb, III, IV and V had significantly increased levels of apolipoprotein C-III (22 +/- 7; 23 +/- 6, and 54 +/- 12, respectively). The levels of apo C-III in patients with type V were significantly higher (P less than 0.001) than in normal or other hyperlipoproteinemic phenotypes.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7370291     DOI: 10.1016/0005-2760(80)90016-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

1.  Impaired postprandial lipemic response in chronic kidney disease.

Authors:  Jeffrey M Saland; Lisa M Satlin; Jeanna Zalsos-Johnson; Serge Cremers; Henry N Ginsberg
Journal:  Kidney Int       Date:  2016-05-07       Impact factor: 10.612

2.  Plasma lipid, lipoprotein and apolipoprotein profiles in Nigerian university athletes and non-athletes.

Authors:  O O Oyelola; M A Rufai
Journal:  Br J Sports Med       Date:  1993-12       Impact factor: 13.800

3.  [Apolipoproteinopathies].

Authors:  G Assmann
Journal:  Klin Wochenschr       Date:  1983-02-15

4.  Alterations in levels of apolipoprotein C-III and C-II/C-III ratios in patients with liver disease.

Authors:  S Koga; K Yamamoto; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1984-02

5.  Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia.

Authors:  Ann C Skulas-Ray; Petar Alaupovic; Penny M Kris-Etherton; Sheila G West
Journal:  J Clin Lipidol       Date:  2014-12-11       Impact factor: 4.766

6.  Lipid and apolipoprotein levels during therapy with pinacidil combined with hydrochlorothiazide.

Authors:  C N Corder; M R Goldberg; P A Alaupovic; M D Price; S S Furste
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.

Authors:  C S Wang; W J McConathy; H U Kloer; P Alaupovic
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

8.  Apolipoproteins A-I, B, and C-III in young adult Cherokee with metabolic syndrome with or without type 2 diabetes.

Authors:  Wenyu Wang; Sohail Khan; Piers Blackett; Petar Alaupovic; Elisa Lee
Journal:  J Clin Lipidol       Date:  2012-07-02       Impact factor: 4.766

9.  Isolation and characterization of apolipoprotein B-48 and B-100 very low density lipoproteins from type III hyperlipoproteinemic subjects.

Authors:  R W Milne; P K Weech; L Blanchette; J Davignon; P Alaupovic; Y L Marcel
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

Review 10.  Lipoprotein metabolism in chronic renal insufficiency.

Authors:  Jeffrey M Saland; Henry N Ginsberg
Journal:  Pediatr Nephrol       Date:  2007-03-28       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.